NEW YORK, April 28 (UPI) -- Pfizer said Friday it has won conditional European approval of Sutent for advanced kidney cancer and a rare intestinal cancer.
Pfizer said the recommendation, which came from the Committee for Human Medicinal Products, means the company will submit additional data to confirm the risk-benefit of Sutent for advanced-kidney-cancer patients.
The marketing authorization, if approved, would be for the treatment of metastatic renal cell carcinoma patients who fail on interferon alpha or interleukin-2-based therapy, and for the treatment of gastrointestinal stromal tumor patients who are resistant or intolerant to imatinib mesylate.
The Food and Drug Administration approved Sutent in January for the treatment of the two cancers.
The drug, which is administered orally, is a multi-kinase inhibitor that attacks cancer by inhibiting the growth and blood supply of tumors.
